High Risk: The Debate Over the Price of Specialty Drugs and Zika Virus
In an interview with CFIF, Dr. Scott Gottlieb, Resident Fellow at the American Enterprise Institute, discusses the history and regulations surrounding drug prices, who should finance important medical advancements, and the continuing Zika threat.
Back in the 1960s, as large numbers of black students were entering a certain Ivy League university for the first time, someone asked a chemistry professor — off the record — what his response to them was. He said, "I give them all A's and B's. To hell with them."
Since many of those students were admitted with lower academic qualifications than other students, he knew that honest grades in a tough subject like chemistry could lead to lots of failing grades, and that in turn would lead to lots of time-wasting hassles — not just from the students, but…
"The first Clinton-Trump debate was roughly a draw -- which is bad news for her, because she needs to turn this race around, and she failed. ...Donald Trump remains the candidate of change; Hillary Clinton, the tribune of the status quo."…[more]